keyword
MENU ▼
Read by QxMD icon Read
search

hepatocellular carcinoma immunotherapy

keyword
https://www.readbyqxmd.com/read/29785403/immunotherapy-for-hepatocellular-carcinoma-current-advances-and-future-expectations
#1
REVIEW
Yingjun Xie, Yien Xiang, Jiyao Sheng, Dan Zhang, Xiaoxiao Yao, Yongsheng Yang, Xuewen Zhang
Primary liver cancer is a common kind of digestive cancers with high malignancy, causing 745,500 deaths each year. Hepatocellular carcinoma is the major pathological type of primary liver cancer. Traditional treatment methods for patients with hepatocellular carcinoma have shown poor efficacy in killing residual cancer cells for a long time. In recent years, tumor immunotherapy has emerged as a promising method owing to its safety and efficacy with respect to delaying the progression of advanced tumors and protecting postoperative patients against tumor relapse and metastasis...
2018: Journal of Immunology Research
https://www.readbyqxmd.com/read/29784005/cd8-t-cells-mediate-the-antitumor-activity-of-frankincense-and-myrrh-in-hepatocellular-carcinoma
#2
Chun Xu, Xian Lu, Wei Liu, Anxian Chen, Gang Meng, Hailin Zhang, Binghua Li, Yonghui Zhang, Junhua Wu, Jiwu Wei
BACKGROUND: Tumor-promoting inflammation is an emerging hallmark of cancer, which participates in both cancer progression and immune escape. Hepatocellular carcinoma (HCC) is a typical inflammation-related cancer with an extremely poor prognosis. Frankincense and myrrh are anti-inflammation agents commonly used in clinic. The purpose of this study is to investigate whether extract of frankincense and myrrh (FM) downregulates inflammatory microenvironment of HCC and thereby restores antitumor immune responses...
May 21, 2018: Journal of Translational Medicine
https://www.readbyqxmd.com/read/29770170/targeted-therapy-or-immunotherapy-optimal-treatment-in-hepatocellular-carcinoma
#3
REVIEW
Merly Contratto, Jennifer Wu
Hepatocellular carcinoma (HCC) is the fifth leading cause of cancer mortality in the United States and the second leading cause of cancer mortality worldwide. Sorafenib is the only food and drug administration (FDA) approved as first line systemic treatment in HCC. Regorafenib and nivolumab are the only FDA approved second line treatment after progression on sorafenib. We will discuss all potential first and second line options in HCC. In addition, we also will explore sequencing treatment options in HCC, and examine biomarkers that can potentially predict benefits from treatments such as immune checkpoint inhibitor...
May 15, 2018: World Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29740200/emergence-of-immunotherapy-as-a-novel-way-to-treat-hepatocellular-carcinoma
#4
REVIEW
Naofumi Mukaida, Yasunari Nakamoto
Tumor immunity proceeds through multiple processes, which consist of antigen presentation by antigen presenting cells (APCs) to educate effector cells and destruction by the effector cytotoxic cells. However, tumor immunity is frequently repressed at tumor sites. Malignantly transformed cells rarely survive the attack by the immune system, but cells that do survive change their phenotypes to reduce their immunogenicity. The resultant cells evade the attack by the immune system and form clinically discernible tumors...
May 7, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29721392/bufalin-suppresses-migration-and-invasion-of-hepatocellular-carcinoma-cells-elicited-by-poly-i-c-therapy
#5
Yinglu Feng, Yongan Chen, Yongbin Meng, Qingxin Cao, Qun Liu, Changquan Ling, Chen Wang
The Toll-like receptor 3 (TLR3) agonists as polyriboinosinic-polyribocytidylic acid (poly (I:C)) have been implicated as potential immunotherapy adjuvant for cancer whereas the exact roles of TLR3 agonists in hepatocellular carcinoma (HCC) treatment have not been clearly evaluated. In consistent with previous reports, we found that poly (I:C) triggering of TLR3 inhibited cell proliferation and induced apoptosis in HCC cells. However, poly (I:C), when used at lower concentration that cannot remarkably inhibit proliferation and induce apoptosis in HCC cells, enhanced the migration and invasion in vitro and the metastasis in vivo...
2018: Oncoimmunology
https://www.readbyqxmd.com/read/29715456/long-noncoding-rna-pvt1-inhibits-interferon-%C3%AE-mediated-therapy-for-hepatocellular-carcinoma-cells-by-interacting-with-signal-transducer-and-activator-of-transcription-1
#6
Hongda Ding, Junpeng Liu, Baiming Liu, Yongchao Zeng, Pengrui Chen, Yang Su
Long noncoding RNA (LncRNA) PVT1 has recently been reported to be involved in the development of hepatocellular carcinoma (HCC) and hsigh expression of oncogenic PVT1 is associated with poor prognosis of HCC. Interferon-α (IFN-α) has been used in clinic for HCC therapy. However, whether PVT1 is involved in the IFN-α therapy for HCC is completely unknown. Our study found that high PVT1 expression in HCC cells is associated with high unmethylation in PVT1 promoter region. IFN-α treatment further increases PVT1 expression in HCC cells by enhancing H3K4me3 modification on the promoter...
April 28, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29707157/microbiota-effects-on-cancer-from-risks-to-therapies
#7
REVIEW
Domenica Rea, Giovanni Coppola, Giuseppe Palma, Antonio Barbieri, Antonio Luciano, Paola Del Prete, Sabrina Rossetti, Massimiliano Berretta, Gaetano Facchini, Sisto Perdonà, Maria Caterina Turco, Claudio Arra
Gut microbiota, a group of 1014 bacteria, eukaryotes and virus living in gastrointestinal tract, is crucial for many physiological processes in particular plays an important role in inflammatory and immune reactions. Several internal and external factors can influence this population, and shifts in their composition, have been demonstrated to contribute and affect different diseases. During dysbiosis several bacteria related to inflammation, one of the most necessary factors in carcinogenesis; it has been shown that some bacterial strains through deregulation of different signals/pathways may affect tumor development through the production of many factors...
April 3, 2018: Oncotarget
https://www.readbyqxmd.com/read/29705792/outlook-immunotherapy-in-gastrointestinal-carcinoma-innovative-strategies
#8
Markus Moehler, Katrin Göpfert, Heinz-Josef Lenz
Immune checkpoint inhibitors are emerging as a therapeutic approach for patients with advanced or metastatic gastrointestinal malignancies following the recent Food and Drug Administration and Asian approvals for colorectal, gastric, and hepatocellular carcinoma. As discussed in earlier articles, phase I-II trials demonstrate quite positive clinical activity, particularly in patients with immunogenic cancer subtypes. This outreach paper discusses some of the next innovative immunotherapy strategies under development...
2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29705790/immunotherapy-of-hepatocellular-carcinoma
#9
Bernd Heinrich, Carolin Czauderna, Jens U Marquardt
Hepatocellular carcinoma (HCC) is one of the most deadly and rapidly evolving cancers worldwide. The current systemic treatment strategies in advanced tumor stages remain limited despite promising preclinical and early-phase clinical results for some compounds, highlighting an unmet clinical need. Since the majority of HCCs evolve in the background of a chronic inflammatory liver damage, HCCs can be considered a paradigm for inflammation-induced cancers, which renders immunotherapeutic strategies particularly promising for this tumor entity...
2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29702018/percutaneous-ablation-for-hepatocellular-carcinoma
#10
Jeffrey L Weinstein, Muneeb Ahmed
OBJECTIVE: The purpose of this article is to discuss the use, comparative efficacy, and general technical considerations of percutaneous ablation, alone or in combination with other therapies, for the treatment of hepatocellular carcinoma (HCC). CONCLUSION: Percutaneous ablation is a mainstay treatment for early-stage HCC, offering survival comparable to that of surgical resection for small lesions. It can act as a primary curative therapy or bridge therapy for patients waiting to undergo liver transplant...
April 27, 2018: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/29673952/expression-of-c19mc-mirnas-in-hcc-associates-with-stem-cell-features-and-the-cancer-testis-genes-signature
#11
Claudia Augello, Federico Colombo, Andrea Terrasi, Elena Trombetta, Marco Maggioni, Laura Porretti, Giorgio Rossi, Silvana Guerneri, Rosamaria Silipigni, Silvano Bosari, Valentina Vaira
BACKGROUND: Intratumor heterogeneity of hepatocellular carcinoma (HCC) and, among HCC cell subsets, the cancer stem cell population (hCSC), is responsible for therapeutic resistance and disease relapse. AIMS: To characterize hCSC-enriched HCCs at the molecular level. METHODS: Side population (SP) was used to identify the hCSCs in multiple tumor sampling from different patients and primary HCCs cultures. FACS was used to immunoprofile cultures...
March 30, 2018: Digestive and Liver Disease
https://www.readbyqxmd.com/read/29670256/deviations-of-the-immune-cell-landscape-between-healthy-liver-and-hepatocellular-carcinoma
#12
Nataliya Rohr-Udilova, Florian Klinglmüller, Rolf Schulte-Hermann, Judith Stift, Merima Herac, Martina Salzmann, Francesca Finotello, Gerald Timelthaler, Georg Oberhuber, Matthias Pinter, Thomas Reiberger, Erika Jensen-Jarolim, Robert Eferl, Michael Trauner
Tumor-infiltrating immune cells are highly relevant for prognosis and identification of immunotherapy targets in hepatocellular carcinoma (HCC). The recently developed CIBERSORT method allows immune cell profiling by deconvolution of gene expression microarray data. By applying CIBERSORT, we assessed the relative proportions of immune cells in 41 healthy human livers, 305 HCC samples and 82 HCC adjacent tissues. The obtained immune cell profiles provided enumeration and activation status of 22 immune cell subtypes...
April 18, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29667374/hepatocellular-carcinoma-prospects-for-nk-cell-immunotherapy
#13
REVIEW
N Kumar, S I Khakoo
Liver disease is a growing cause of death in the UK and the incidence of hepatocellular carcinoma (HCC) is rising (http://www.cancerresearchuk.org/). The combination of an immunosuppressive environment within the liver and suboptimal host anti-tumour immune responses may account for the poor survival outcome of HCC. Understanding how tumours evade immune recognition coupled with new insights into the unique immunological environment within the liver will be critical to developing liver-specific immunotherapies...
April 17, 2018: HLA
https://www.readbyqxmd.com/read/29665588/current-technique-and-application-of-percutaneous-cryotherapy
#14
Andreas H Mahnken, Alexander Marc König, Jens Holger Figiel
PURPOSE:  Local ablative therapies have become an established treatment option in interventional oncology. Radiofrequency ablation (RFA) and microwave ablation (MWA) are a standard of care in the treatment of hepatocellular carcinoma (HCC). Currently, there is an increasing interest in cryotherapy, one of the oldest ablation techniques. It has some unique characteristics with regard to technology and mechanism of action. MATERIALS AND METHODS:  A systematic literature search using the terms cryotherapy, cryosurgery and cryoablation was performed...
April 17, 2018: RöFo: Fortschritte Auf Dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
https://www.readbyqxmd.com/read/29663340/molecular-signatures-in-hepatocellular-carcinoma-a-step-toward-rationally-designed-cancer-therapy
#15
REVIEW
Derek J Erstad, Bryan C Fuchs, Kenneth K Tanabe
Molecular characterization of hepatocellular carcinoma (HCC) has greatly improved our understanding of disease pathogenesis. Mutational analysis, RNA and microRNA expression profiling, and epigenetic characterization have revealed common aberrations in oncogenes and tumor suppressors that correlate with disease biology and serve as a guide for the rational design of targeted therapies. These approaches have also led to the discovery of novel targets, including mutations in isocitrate dehydrogenase and chromatin remodeling enzymes...
April 17, 2018: Cancer
https://www.readbyqxmd.com/read/29662830/combination-cancer-immunotherapy-in-hepatocellular-carcinoma
#16
EDITORIAL
Masatoshi Kudo
No abstract text is available yet for this article.
March 2018: Liver Cancer
https://www.readbyqxmd.com/read/29625896/co-inhibitory-molecule-b7-superfamily-member-1-expressed-by-tumor-infiltrating-myeloid-cells-induces-dysfunction-of-anti-tumor-cd8-t-cells
#17
Jing Li, Younghee Lee, Yanjian Li, Yu Jiang, Huiping Lu, Wenjuan Zang, Xiaohong Zhao, Liguo Liu, Yang Chen, Haidong Tan, Zhiying Yang, Michael Q Zhang, Tak W Mak, Ling Ni, Chen Dong
The molecular mechanisms whereby CD8+ T cells become "exhausted" in the tumor microenvironment remain unclear. Programmed death ligand-1 (PD-L1) is upregulated on tumor cells and PD-1-PD-L1 blockade has significant efficacy in human tumors; however, most patients do not respond, suggesting additional mechanisms underlying T cell exhaustion. B7 superfamily member 1 (B7S1), also called B7-H4, B7x, or VTCN1, negatively regulates T cell activation. Here we show increased B7S1 expression on myeloid cells from human hepatocellular carcinoma correlated with CD8+ T cell dysfunction...
March 29, 2018: Immunity
https://www.readbyqxmd.com/read/29602780/development-of-a-new-patient-derived-xenograft-humanised-mouse-model-to-study-human-specific-tumour-microenvironment-and-immunotherapy
#18
Yue Zhao, Timothy Wai Ho Shuen, Tan Boon Toh, Xue Ying Chan, Min Liu, Sue Yee Tan, Yong Fan, Hechuan Yang, Shridhar Ganpathi Lyer, Glenn Kunnath Bonney, Eva Loh, Kenneth Tou En Chang, Thiam Chye Tan, Weiwei Zhai, Jerry Kok Yen Chan, Edward Kai-Hua Chow, Cheng Ean Chee, Guan Huei Lee, Yock Young Dan, Pierce Kah-Hoe Chow, Han Chong Toh, Seng Gee Lim, Qingfeng Chen
OBJECTIVE: As the current therapeutic strategies for human hepatocellular carcinoma (HCC) have been proven to have limited effectiveness, immunotherapy becomes a compelling way to tackle the disease. We aim to provide humanised mouse (humice) models for the understanding of the interaction between human cancer and immune system, particularly for human-specific drug testing. DESIGN: Patient-derived xenograft tumours are established with type I human leucocyte antigen matched human immune system in NOD- scid Il2rg-/- (NSG) mice...
March 30, 2018: Gut
https://www.readbyqxmd.com/read/29601672/mri-guided-interventional-natural-killer-cell-delivery-for-liver-tumor-treatment
#19
Zhanliang Su, Xifu Wang, Linfeng Zheng, Tianchu Lyu, Matteo Figini, Bin Wang, Daniel Procissi, Junjie Shangguan, Chong Sun, Liang Pan, Lei Qin, Bin Zhang, Yury Velichko, Riad Salem, Vahid Yaghmai, Andrew C Larson, Zhuoli Zhang
While natural killer (NK) cell-based adoptive transfer immunotherapy (ATI) provides only modest clinical success in cancer patients. This study was hypothesized that MRI-guided transcatheter intra-hepatic arterial (IHA) infusion permits local delivery to liver tumors to improve outcomes during NK-based ATI in a rat model of hepatocellular carcinoma (HCC). Mouse NK cells were labeled with clinically applicable iron nanocomplexes. Twenty rat HCC models were assigned to three groups: transcatheter IHA saline infusion as the control group, transcatheter IHA NK infusion group, and intravenous (IV) NK infusion group...
March 30, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29601471/nanopulse-stimulation-nps-induces-tumor-ablation-and-immunity-in-orthotopic-4t1-mouse-breast-cancer-a-review
#20
REVIEW
Stephen J Beebe, Brittany P Lassiter, Siqi Guo
Nanopulse Stimulation (NPS) eliminates mouse and rat tumor types in several different animal models. NPS induces protective, vaccine-like effects after ablation of orthotopic rat N1-S1 hepatocellular carcinoma. Here we review some general concepts of NPS in the context of studies with mouse metastatic 4T1 mammary cancer showing that the postablation, vaccine-like effect is initiated by dynamic, multilayered immune mechanisms. NPS eliminates primary 4T1 tumors by inducing immunogenic, caspase-independent programmed cell death (PCD)...
March 30, 2018: Cancers
keyword
keyword
11168
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"